Get startedLog in
    Picture of Supernus Pharmaceuticals logo

    SUPN — Supernus Pharmaceuticals News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareBalancedMid CapHigh Flyer
    All News

    Brief: Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted For Review By FDA

    Picture of Supernus Pharmaceuticals logoSupernus Pharmaceuticals
    19/08/2024 12:36
    Aug 19 (Reuters) - Supernus Pharmaceuticals Inc
 SUPN.O :
    * SUPERNUS ANNOUNCES SPN-830 APOMORPHINE INFUSION DEVICE NDA
ACCEPTED FOR REVIEW BY FDA
    * SUPERNUS PHARMACEUTICALS INC: RESUBMISSION IS NOW
CONSIDERED
FILED, WITH A USER FEE GOAL DATE (PDUFA DATE) OF FEBRUARY 1,
2025.

Source text for Eikon:  ID:nGNX4c0tfs 
Further company coverage:  SUPN.O 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Supernus Pharmaceuticals

    See all news